23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › TriSalus Life Sciences, Inc. › 2025-2026

TriSalus Life Sciences, Inc. 2025-2026 Proxy Voting Records

At TriSalus Life Sciences, Inc.'s shareholder meeting held May 14, 2026, in the 2025-2026 proxy season, 89 asset managers reported how they voted in their SEC Form N-PX filings, covering 594 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To consider and vote upon, on an advisory basis, the compensation of the Company's named… — TriSalus Life Sciences, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: TriSalus Life Sciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 14, 2026.

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and TriSalus Life Sciences, Inc.’s Form 8-K, filed May 14, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.

  • 5Reported items
  • 89Asset managers
  • 594Fund votes
  • May 14, 2026Meeting date

Results at a glance

Meeting of May 14, 2026: 4 items on TriSalus Life Sciences, Inc.’s Form 8-K, filed May 14, 2026: 2 elected · 2 approved.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2025-2026

Explore TriSalus Life Sciences, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by TriSalus Life Sciences, Inc.

These tallies are TriSalus Life Sciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 14, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

TriSalus Life Sciences, Inc. — official shareholder meeting results, meeting held May 14, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Mary Szela 31,393,310---- 2,614,2467,721,120 92%Elected—
Elect Director: Gary Gordon 31,339,161---- 2,668,3957,721,120 92%Elected—
2. Appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the fiscal year ending December 31, 2026 41,098,38528,667601,624 ---- 99.9%Approved—
4. Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers 32,625,0821,206,105176,369 --7,721,120 96%Approved—

Source: TriSalus Life Sciences, Inc., Form 8-K, filed with the SEC on May 14, 2026 — read the filing on EDGAR.

How asset managers voted at the TriSalus Life Sciences, Inc. 2025-2026 meeting

Each item below shows how the 89 asset managers that disclosed a TriSalus Life Sciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of TriSalus Life Sciences, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Gary Gordon

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 31,339,161WITHHELD: 2,668,395
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: To elect the Board's two nominees for directors named as nominees in the Proxy Statement to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation, or removal: Gary Gordon

TriSalus Life Sciences, Inc.’s own tally for this item (“Elect Director: Gary Gordon”): 31,339,161 for, 2,668,395 withheld, per its Form 8-K filed May 14, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The two nominees for Directors were elected to serve three-year terms to expire at the annual meeting of stockholders in 2029, as follows:”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 4,239,562 for, 117,607 withheld, 3 abstained.

FOR
FOR: 4,239,562ABSTAIN: 3WITHHOLD: 117,607
Largest asset managers voting on “To elect the Board's two nominees for directors named as nominees in the Proxy Statement to hold office until ” at TriSalus Life Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,483,4840 30For
WASATCH FUNDS TRUST1,424,9300 00For
BlackRock662,0100 00For
Fidelity231,9600 00For
Royce200,0000 00For
Charles Schwab92,1560 00For
BRIDGEWAY FUNDS INC00 051,691Withhold
TIAA36,5500 00For
Goldman Sachs22,5220 00For
World Funds Trust17,5000 00For
Lincoln Financial00 015,500Withhold
AIG/SunAmerica00 014,802Withhold
Global X13,9250 00For
Equitable12,4070 0580For
Bridge Builder Trust11,6170 00For
State Street00 011,015Withhold
Pacific Life10,9060 00For
Brighthouse00 010,692Withhold
Voya5,2040 00For
ProShares00 05,115Withhold
Nationwide4,6400 00For
DWS00 04,113Withhold
T. Rowe Price3,4570 00For
GPS Funds I2,6700 00For
MARCO INVESTMENT MANAGEMENT LLC2,1410 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

2. Elect Director: Mary Szela

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 31,393,310WITHHELD: 2,614,246
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: To elect the Board's two nominees for directors named as nominees in the Proxy Statement to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation, or removal: Mary Szela

TriSalus Life Sciences, Inc.’s own tally for this item (“Elect Director: Mary Szela”): 31,393,310 for, 2,614,246 withheld, per its Form 8-K filed May 14, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The two nominees for Directors were elected to serve three-year terms to expire at the annual meeting of stockholders in 2029, as follows:”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 4,223,634 for, 133,535 withheld, 3 abstained.

FOR
FOR: 4,223,634ABSTAIN: 3WITHHOLD: 133,535
Largest asset managers voting on “To elect the Board's two nominees for directors named as nominees in the Proxy Statement to hold office until ” at TriSalus Life Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,482,3360 31,148For
WASATCH FUNDS TRUST1,424,9300 00For
BlackRock662,0100 00For
Fidelity231,9600 00For
Royce200,0000 00For
Charles Schwab92,1560 00For
BRIDGEWAY FUNDS INC00 051,691Withhold
TIAA00 036,550Withhold
Goldman Sachs22,5220 00For
World Funds Trust17,5000 00For
Lincoln Financial15,5000 00For
AIG/SunAmerica00 014,802Withhold
Global X13,9250 00For
Equitable12,4070 0580For
Bridge Builder Trust11,6170 00For
State Street11,0150 00For
Pacific Life10,9060 00For
Brighthouse00 010,692Withhold
Voya00 05,204Withhold
ProShares00 05,115Withhold
Nationwide4,6400 00For
DWS00 04,113Withhold
T. Rowe Price3,4570 00For
GPS Funds I2,6700 00For
MARCO INVESTMENT MANAGEMENT LLC2,1410 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

3. Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 32,625,082AGAINST: 1,206,105
Details: description as filed, official tally, votes by 88 asset managers

Description as filed by funds: To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers.

TriSalus Life Sciences, Inc.’s own tally for this item (“4. Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers”): 32,625,082 for, 1,206,105 against — passed, per its Form 8-K filed May 14, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers was approved by the stockholder vote:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 31 asset managers voting on “To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers.” at TriSalus Life Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,483,4852 00For
WASATCH FUNDS TRUST1,424,9300 00For
BlackRock662,0100 00For
Fidelity231,9600 00For
Royce200,0000 00For
Charles Schwab92,1560 00For
BRIDGEWAY FUNDS INC051,691 00Against
TIAA36,5500 00For
Goldman Sachs22,5220 00For
World Funds Trust17,5000 00For
Lincoln Financial15,5000 00For
AIG/SunAmerica14,8020 00For
Global X13,9250 00For
Equitable12,9870 00For
Bridge Builder Trust11,6170 00For
State Street11,0150 00For
Pacific Life10,9060 00For
Brighthouse10,6920 00For
Voya5,2040 00For
ProShares5,1150 00For
Nationwide4,6400 00For
DWS4,1130 00For
T. Rowe Price3,4570 00For
GPS Funds I2,6700 00For
Principal1,7260 00For

Fund voting reports, all 31 managers: 4,301,547 for, 53,484 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 65 asset managers voting on “To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers.” at TriSalus Life Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
First Light Asset Management, LLC4,472,9630 00For
Nantahala Capital Management, LLC1,548,4420 00For
WASATCH ADVISORS LP1,434,9260 00For
Cerity Partners LLC787,1320 00For
Focus Partners Wealth746,7340 00For
THOMPSON SIEGEL & WALMSLEY LLC534,5030 00For
GEODE CAPITAL MANAGEMENT, LLC347,4470 00For
KENNEDY CAPITAL MANAGEMENT LLC184,423156,230 00Mixed
State Street293,792285 00For
APIS CAPITAL ADVISORS, LLC242,0000 00For
Vanguard235,4760 00For
BlackRock188,341104 00For
PERKINS CAPITAL MANAGEMENT INC181,0510 00For
BANK OF AMERICA NA178,2490 00For
Northern Trust168,5400 00For
MELLON INVESTMENTS Corp102,7880 00For
Charles Schwab92,1580 00For
INTRUST BANK NA66,0000 00For
BRIDGEWAY CAPITAL MANAGEMENT, LLC056,191 00Against
FORMULA GROWTH LTD50,0000 00For
MSD Partners, L.P.39,9990 00For
Nuveen36,5500 00For
Goldman Sachs12,7710 00For
T. Rowe Price12,3880 00For
JPMorgan012,367 00Against

Institutional-manager reports, all 65 managers: 12,040,710 for, 249,146 against, 4,331 1 year. Showing the 25 largest; every one is in the interactive database (link above).

4. To consider and vote upon, on an advisory basis, the frequency with which the Company should conduct future stockholder…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

100% Fund and manager reports combined; may count the same shares twice · no official result

FOR1 YEAR
Details: description as filed, votes by 86 asset managers

Description as filed by funds: To consider and vote upon, on an advisory basis, the frequency with which the Company should conduct future stockholder advisory votes on named executive officer compensation.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 31 asset managers voting on “To consider and vote upon, on an advisory basis, the frequency with which the Company should conduct future st” at TriSalus Life Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
WASATCH FUNDS TRUST00 00--
BlackRock00 00--
Fidelity00 00--
Royce00 200,0000Abstain
Charles Schwab00 00--
BRIDGEWAY FUNDS INC00 00--
TIAA00 00--
Goldman Sachs00 00--
World Funds Trust00 00--
Lincoln Financial00 00--
AIG/SunAmerica00 00--
Global X00 00--
Equitable00 00--
Bridge Builder Trust00 00--
State Street00 00--
Pacific Life00 00--
Brighthouse10,6920 00For
Voya00 00--
ProShares00 00--
Nationwide00 00--
DWS00 00--
T. Rowe Price00 00--
GPS Funds I00 00--
Principal00 00--

Fund voting reports, all 31 managers: 10,692 for, 200,000 abstained, 4,140,180 1 year, 2,500 unknown, 1,660 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 63 asset managers voting on “To consider and vote upon, on an advisory basis, the frequency with which the Company should conduct future st” at TriSalus Life Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
First Light Asset Management, LLC4,472,9630 00For
WASATCH ADVISORS LP00 00--
Cerity Partners LLC00 00--
Focus Partners Wealth00 00--
THOMPSON SIEGEL & WALMSLEY LLC00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
KENNEDY CAPITAL MANAGEMENT LLC00 00--
State Street00 00--
APIS CAPITAL ADVISORS, LLC242,0000 00For
Vanguard00 00--
BlackRock00 00--
PERKINS CAPITAL MANAGEMENT INC00 00--
BANK OF AMERICA NA00 00--
Northern Trust00 00--
MELLON INVESTMENTS Corp00 00--
Charles Schwab00 00--
INTRUST BANK NA00 00--
BRIDGEWAY CAPITAL MANAGEMENT, LLC00 00--
MSD Partners, L.P.00 00--
Nuveen00 00--
Goldman Sachs00 00--
T. Rowe Price00 00--
JPMorgan00 00--
STIFEL NICOLAUS & CO INC \MO\00 00--
NEW YORK STATE COMMON RETIREMENT FUND00 00--

Institutional-manager reports, all 63 managers: 4,724,703 for, 5,974,310 1 year. Showing the 25 largest; every one is in the interactive database (link above).

5. Appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the fiscal year ending…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 41,098,385AGAINST: 28,667
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF GRANT THORNTON LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

TriSalus Life Sciences, Inc.’s own tally for this item (“2. Appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the fiscal year ending December 31, 2026”): 41,098,385 for, 28,667 against — passed, per its Form 8-K filed May 14, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the fiscal year ending December 31, 2026 was ratified by the stockholder vote:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 4,357,172 for.

FOR
FOR: 4,357,172
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF GRANT THORNTON LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM” at TriSalus Life Sciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,483,4870 00For
WASATCH FUNDS TRUST1,424,9300 00For
BlackRock662,0100 00For
Fidelity231,9600 00For
Royce200,0000 00For
Charles Schwab92,1560 00For
BRIDGEWAY FUNDS INC51,6910 00For
TIAA36,5500 00For
Goldman Sachs22,5220 00For
World Funds Trust17,5000 00For
Lincoln Financial15,5000 00For
AIG/SunAmerica14,8020 00For
Global X13,9250 00For
Equitable12,9870 00For
Bridge Builder Trust11,6170 00For
State Street11,0150 00For
Pacific Life10,9060 00For
Brighthouse10,6920 00For
Voya5,2040 00For
ProShares5,1150 00For
Nationwide4,6400 00For
DWS4,1130 00For
T. Rowe Price3,4570 00For
GPS Funds I2,6700 00For
MARCO INVESTMENT MANAGEMENT LLC2,1410 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

Largest TriSalus Life Sciences, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 61,416,535 shares outstanding at the time of that meeting.

Fund voting reports: top TriSalus Life Sciences, Inc. shareholders by shares voted on “To consider and vote upon, on an advisory basis, the compensation of the Company's named…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 2.42%
2WASATCH FUNDS TRUST 2.32%
3BlackRock 1.08%
4Fidelity 0.38%
5Royce 0.33%
6Charles Schwab 0.15%
7BRIDGEWAY FUNDS INC 0.08%
8TIAA 0.06%
9Goldman Sachs 0.04%
10World Funds Trust 0.03%
Institutional-manager reports: top TriSalus Life Sciences, Inc. shareholders by shares voted on “To consider and vote upon, on an advisory basis, the compensation of the Company's named…”, 2025-2026
#Asset manager % of shares outstanding
1First Light Asset Management, LLC 7.28%
2Nantahala Capital Management, LLC 2.52%
3WASATCH ADVISORS LP 2.34%
4Cerity Partners LLC 1.28%
5Focus Partners Wealth 1.22%
6THOMPSON SIEGEL & WALMSLEY LLC 0.87%
7GEODE CAPITAL MANAGEMENT, LLC 0.57%
8KENNEDY CAPITAL MANAGEMENT LLC 0.55%
9State Street 0.48%
10APIS CAPITAL ADVISORS, LLC 0.39%

Reported TriSalus Life Sciences, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

TriSalus Life Sciences, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder % outstanding Disclosure
Frankenius Equity AB 11.38% DEF14A
First Light Asset Management, LLC 10.74% 13G
Utmost Group PLC 5.70% 13G
James J. Pallotta 5.19% 13G
Mats Wahlström 4.88% DEF14A
David J. Matlin 4.15% DEF14A
Kerry Hicks 3.83% DEF14A
Michael P. Stansky 2.95% DEF14A
Vanguard Group 2.49% 13F
BlackRock 2.44% 13F

Percentages above are of 61,416,535 shares outstanding, as reported by TriSalus Life Sciences, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from TriSalus Life Sciences, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.

TriSalus Life Sciences, Inc. proxy season coverage: 2025-2026 (this page).

Cite this page

proxyvotesnow.com, “TriSalus Life Sciences (TLSI) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/trisalus-life-sciences-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.